National Institute of Allergy and Infectious Diseases (NIAID)

FLC Region

Security Lab

No

Address

Technology Transfer and Intellectual Property Office
5601 Fishers Lane
Bethesda, MD 20892-9804
United States

Laboratory Representative

Description

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.

Tech Areas

Available Technologies
Displaying 1 - 10 of 190
4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4
A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development
A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening
A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening
A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases
A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases
A Newly Discovered Bacterium in the Family Acetobacteraceae
A Newly Discovered Bacterium in the Family Acetobacteraceae
A Novel Fusion Protein for Inhibiting HIV Budding
A Novel Fusion Protein for Inhibiting HIV Budding

Pages

Funding

New Direct-to-SBIR Phase II Funding Award for NIAID Intramural Diagnostic Inventions

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), is pleased to announce the first NIAID Small Business Innovation Research-Technology Transfer (SBIR-TT) Direct-to-Phase II awards to move commercially viable diagnostic technologiesfrom NIAID intramural research laboratories into the marketplace. Direct-to-Phase II awards of up to $2M allow small businesses to compete even if they did not receive a Phase I SBIR award for research in the same area. An SBIR Phase II research and development plan tests the viability of the technology scientifically as well as its potential for commercialization. This Funding Opportunity Announcement (FOA)offers 18 diagnostic inventions for further development by small businesses. The list includes technologies related to hepatitis, cancer, tropical diseases, as well as other areas. As the lead federal organization conducting and supporting scientific research on infectious and immunologic diseases, NIAID carries out basic, applied, and clinicalinvestigations within intramurallaboratories and provides extramural grant, cooperative agreement, and contractsupport to research scientists worldwide. Any project that fits within the NIAID mission and relies on the use of the NIAID'u s intramural technologieslisted is eligible for this award.

Please contact Dr. Haiqing Li to discuss NIAID inventions. See FOA: NIAID SBIR - Technology Transfer Direct Phase II (SBIR-TT) (R44) for the details on eligibility and applying, or see the FAQ page for additional information.

No Programs for this lab
Facilities
Displaying 1 - 3 of 3
NIAID Core Facilities (Various)
Office of Chief Scientist, Integrated Research Facility (OCSIRF)
Rocky Mountain Laboratories (RML)
No Equipment for this lab
No publications for this lab
No Notices for this lab
No success stories for this lab
Submit an Success Story